Navigation Links
US Cancer Vaccine Market Analysis
Date:9/17/2012

can be expected to come up soon with promising candidates, such as Lucanix and Stimuvax having entered phase 3 trials.

The report also covers the FDA's vaccine approval process and its guidance to the industry for developing therapeutic cancer vaccines. The therapeutic vaccines currently account only for about 15% share in the US cancer vaccine market but this share can be expected to increase drastically post 2016 with such high focus on developing therapeutics for other cancer types.

The report "US Cancer Vaccine Market Analysis", is an outcome of an extensive research and prudent analysis of the cancer vaccine market in the world and in US. It provides an effective analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Further, the report provides an in-depth analysis on the pipeline cancer vaccines in phase 1-4 clinical stages for most prevalent cancers in US. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines for clinical proceedings of cancer therapeutic vaccines has also been provided. The report also provides competitive analysis of the promising players in the market along with their key strategies to increase their penetration in the market.

1. Analyst View2. Research Methodology3. Cancer Statistics by Demographics3.1 Prevalence, Incidences and Mortality (2008-2016)3.2 Leading States by Incidence3.3 Leading Cancers by Incidence3.3.1 Male Cancer Incidences3.3.2 Female Cancer Incidences3.3.3 Age-Group4. Cancer Vaccines Market Outlook4.1 Market Analysis and Segmentation4.2 Key Product Analysis4.2.1 Provenge4.2.1.1 Market Analysis4.2.1.2 Restraints4.2.2 HPV Vaccine4.2.2.1 Gardasil4.2.2.1.1 Market Analysis4.2.2.1.2 Restraints4.2.2.2 Cervarix4.2.2.2.1 Market Analysis4.2.2.2.2 Restraints4.2.3 HBV Vaccines4.2.3.1 Market Analysis4.2.3.2 Market Re
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
2. Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
3. Prostate Cancer: The End of Life As Men Know It?
4. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
5. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
6. Frost & Sullivan Lauds IncellDx for Developing a Novel, Non-invasive Method for Cervical Cancer Testing
7. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
8. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Urologists And Henry Schein Team Up To Urge Families To Put A Prostate Cancer Check-Up On The Back To School List For Dad
10. The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
11. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... Given the nondiscretionary nature of ... and Vegetable Markets industry is generally stable; ... operators over the five years to 2014. Furthermore, ... demographic trends, including a focus on healthy eating ... fruit and vegetable consumption declined at an annualized ...
(Date:9/23/2014)... will present the results of their cancer research ... Madrid. , Joint Symposium: ESMO-ASCO: The Evolution ... 29, 11:00 AM - 12:30 PM, Room: Granada, ... Platforms support new forms of cancer clinical research? ... Proffered Paper session: Melanoma and other skin ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... million in supplemental funding to bolster the research of ... preclinical and clinical studies. , This investment encourages researchers ... for considering sex as a fundamental variable in research. ... can obscure key findings related to sex that could ... in greater awareness of the need to study both ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
Breaking Medicine News(10 mins):Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:New hope for beloved family pets 2
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
... shows the NSAID Celebrex may help prevent some non-melanoma ... actinic keratoses lesions and are at high risk for ... of Alabama at Birmingham dermatologist and the study,s lead ... of celecoxib as a chemo-preventive agent for actinic keratoses. ...
... what might be one of the world,s first medicinal body ... have successfully implanted an experimental device in the throat of ... ability to swallow. The device, which could offer an effective ... controlled by pulling on a tiny metal pin that extends ...
... November 30, 2010The Council for Responsible Nutrition (CRN), the ... National Academy of Sciences Institute of Medicine,s (IOM) newly-released ... vitamin D "a modest step in the right ... and positive research that has consistently supported the need ...
... TUESDAY, Nov. 30 (HealthDay News) -- Acupuncture alters the ... finding that suggests the traditional Chinese treatment can effectively ... researchers used functional MRI scans to measure brain activity ... a device fitted to their left ankle. The researchers ...
... sleep apnea (OSA), a sleep disorder associated with obesity, ... arteries, according to a study presented today at the ... (RSNA). "Our study reveals that individuals with obstructive ... of atherosclerosis that puts them at risk for impaired ...
Cached Medicine News:Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2Health News:Celebrex may help prevent some non-melanoma skin cancers 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 3Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 2Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 3Health News:People with sleep apnea at higher risk for aggressive heart disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: